Cerdulatinib

Cerdulatinib is a small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies.[1] It has lowest nM IC50 values against TYK2, JAK1, JAK2, JAK3, FMS, and SYK.[2]

Cerdulatinib

Clinical data
Other names	PRT062070, PRT2070, DMVT-502
Routes of administration	By mouth
Identifiers
IUPAC name 4-(Cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide
CAS Number	1198300-79-6^Y[PubChem]
PubChem CID	44595079
ChemSpider	32822046^Y
UNII	D1LXQ45S1O
Chemical and physical data
Formula	C20H27N7O3S
Molar mass	445.54 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CCS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C(C(=N3)NC4CC4)C(=O)N

It is being developed by Portola Pharmaceuticals; in September 2018 the FDA granted orphan drug status to cerdulatinib for the treatment of peripheral T-cell lymphoma (PTCL).[3]

See also

• Ruxolitinib
• Fostamatinib
• Entospletinib

References

1. Liu D, Mamorska-Dyga A (July 2017). "Syk inhibitors in clinical development for hematological malignancies". Journal of Hematology & Oncology. 10 (1): 145. doi:10.1186/s13045-017-0512-1. PMC 5534090. PMID 28754125.
2. Coffey G, Betz A, DeGuzman F, Pak Y, Inagaki M, Baker DC, et al. (December 2014). "The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer". The Journal of Pharmacology and Experimental Therapeutics. 351 (3): 538–48. doi:10.1124/jpet.114.218164. PMID 25253883.
3. "Investors - News Release - Portola Pharmaceuticals, Inc". phx.corporate-ir.net. September 25, 2018.